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Peroxisome proliferator-activated receptor γ1 (PPARγ1) and liver X receptor α (LXRα) are nuclear receptors
that play pivotal roles in macrophage cholesterol homeostasis and inflammation; key biological processes
in atherogenesis.The activation of PPARγ1 and LXRα by natural or synthetic ligands results in the
transactivation of ABCA1, ABCG1, and ApoE; integral players in cholesterol efflux and reverse cholesterol
transport. In this review, we describe the structure, isoforms, expression pattern, and functional specificity
of PPARs and LXRs. Control of PPARs and LXRs transcriptional activity by coactivators and corepressors
is also highlighted.The specific roles that PPARγ1 and LXRα play in inducing macrophage cholesterol efflux
mediators and antagonizing macrophage inflammatory responsiveness are summarized. Finally, this review
focuses on the recently reported regulatory functions that adipocyte enhancer-binding protein 1 (AEBP1)
exerts on PPARγ1 and LXRα transcriptional activity in the context of macrophage cholesterol homeostasis
and inflammation.
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Structure of PPARs and LXRs
As nuclear hormone receptors, peroxisome
proliferator-activated receptors (PPARs) possess a
canonical domain structure similar to that of other
members of the nuclear hormone receptor superfamily.
At the N-terminus, PPARs harbor a ligand-independent
transactivation (AF-1) sub-domain within the A/B domain,
followed by a DNA binding domain (DBD) containing two
zinc finger motifs, ligand binding domain (LBD), and a
ligand-dependent transactivation (AF-2) domain towards
the C-terminus. DBD and LBD are the most conserved
domains among different isoforms of PPARs. LBD serves
complex functions since it does not only mediate ligand
binding, but it also mediates interaction with RXR, as well
as coactivators and corepressors, in a highly specific
manner [Chen et al., 1996; Gearing et al., 1993].
Structurally, liver X receptors (LXRs) are similar to other
members of the nuclear hormone superfamily. LXRs
contain a poorly characterized N-terminus that has AF-1
domain, followed by a central DNA binding domain (DBD),
and a relatively large C-terminus containing the
ligand-binding domain (LBD) and AF-2 ligand-dependent
domain [Chawla et al., 2001c]. DBD of LXRs contains
two highly conserved zinc finger motifs, characteristic of
other orphan nuclear receptors, which is required for
physical contact between LXR-RXR heterodimers and
LXR response elements (LXREs) in the promoters of
target genes.The LBD of LXRs confer ligand specificity,
heterodimerization with RXRs, as well as interactions
with coactivators and corepressors [Renaud et al., 1995].
Isoforms, expression, and functional
specificity of PPARs and LXRs
PPARα, PPARβ/δ, and PPARγ are three isoforms
encoded by three different genes in eukaryotic cells, and
these three isoforms constitute the PPAR subfamily of
the orphan nuclear hormone receptor superfamily. PPARs
are traditionally known as orphan nuclear receptors due
to the initial lack of knowledge about their physiological
ligands, which are now known to include a wide range of
biomolecules.Whereas PPARα and PPARδ can be
activated by a wide range of saturated and unsaturated
fatty acids [Amri et al., 1995; Forman et al., 1997;
Gottlicher et al., 1992; Kliewer et al., 1997;Yu et al.,
1995], PPARγ prefers polyunsaturated fatty acids as
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(TZDs) (e.g., rosiglitazone, pioglitazone, ciglitazone, and
troglitazone), and α-substituted carboxylic acids (e.g.,
L-165041) are potent synthetic agonists for PPARα
[Willson et al., 2000], PPARγ [Berger et al., 1996;
Lehmann et al., 1995;Willson et al., 1996], and PPARβ/δ
[Berger et al., 1999], respectively.
PPARs are ligand-activated transcription factors that
regulate the expression of a wide range of genes whose
products are critically involved in lipid metabolism. PPARs
are thought to be ubiquitously expressed, with differential
expression patterns among the three isoforms. PPARα,
the first PPAR to be identified, is expressed in many
tissues and cells including the liver, kidney, skeletal
muscle, heart, brown adipose tissue, monocytes,
endothelial cells, and vascular smooth muscle cells
[Braissant et al., 1996; Issemann and Green, 1990].
PPARβ/δ is expressed in a wide range of tissues and
cells, but its expression seems to be highest in the brain,
skin, and adipose tissue [Braissant et al., 1996].
Interestingly, the PPARγ gene is transcribed into three
different mRNA molecules: PPARγ1 and PPARγ2, which
are transcribed from the same promoter by differential
promoter usage and subsequent alternative mRNA
splicing [Zhu et al., 1995], and PPARγ3, which is
transcribed from an independent promoter [Fajas et al.,
1998].Yet, these three mRNA transcripts give rise to only
two PPARγ proteins, PPARγ1 and PPARγ2, due to the
fact that PPARγ3 mRNA is translated into a protein that
is identical to PPARγ1 [Fajas et al., 1998]. PPARγ2
protein, whose expression is restricted to colon and
adipose tissue [Fajas et al., 1997; Fajas et al., 1998;
Tontonoz et al., 1994a], has 30 extra amino acid residues
at its N-terminus compared to PPARγ1, which is
ubiquitously expressed.
Upon ligand binding, PPARs become activated and they
heterodimerize with RXR, which also has three isoforms
designated RXRα, RXRβ, and RXRγ, all of which are
activated by retinoic acid [Mangelsdorf et al., 1992].
PPAR-RXR obligate heterodimers bind to PPAR response
elements (PPREs; direct repeats of AGGNCA separated
by 1 or 2 nucleotides, DR1 and DR2 elements,
respectively) within the promoter regions of their target
genes, leading to gene transactivation. Such PPREs have
been identified in the promoter region of several genes
involved in lipid metabolism including aP2 [Tontonoz et
al., 1994b], phosphenolpyruvate carboxykinase (PEPCK)
[Tontonoz et al., 1995], lipoprotein lipase (LPL)
[Schoonjans et al., 1996], CD36 [Sfeir et al., 1997],
LXRα/β [Chawla et al., 2001b], and ApoE [Galetto et al.,
2001].
LXRs are members of the orphan nuclear receptor
superfamily that were first identified in the liver, hence
their name [Apfel et al., 1994;Willy et al., 1995].Two
isoforms have already been characterized, namely LXRα
and LXRβ, the latter being ubiquitously expressed [Song
et al., 1994], while the expression of the former is more
restricted in the kidney, spleen, adipose tissue, lung,
intestine, skeletal muscle, and macrophages [Apfel et al.,
1994; Peet et al., 1998a;Willy et al., 1995]. It is believed
that intracellular cholesterol leads to the production of
LXRs specific physiological ligands, oxysterols [Repa and
Mangelsdorf, 2002]. 24(S),25-epoxycholesterol,
24(S)-hydroxycholesterol, and 22(R)-hydroxycholesterol
are the most abundant and potent oxysterols capable of
activating LXRs in the cell [Janowski et al., 1996]. Potent
and specific pharmacological LXR agonists, such as
T0901317 and GW3965, have been synthesized. Similar
to PPARs, ligand-bound LXRs tend to form heterodimers
with their obligate partner RXR, and activated LXR-RXR
heterodimers are capable of binding to specific DNA
binding sites known as LXREs, which consist of two direct
repeats (AGGTCA) separated by four nucleotides (DR4
elements) [Willy et al., 1995]. LXREs have been identified
in the promoter regions of several genes regulated by
LXRs including ABCA1 [Costet et al., 2000; Schwartz et
al., 2000], ABCG1 [Venkateswaran et al., 2000b], PPARγ
[Seo et al., 2004], and ApoE [Laffitte et al., 2001].
Coactivation and corepression of
PPARs and LXRs
As their names suggest, coactivators and corepressors
are transcription modulators that allow transactivation
and repression of target genes, respectively, by means
of associating with transcription factors that regulate
expression of such genes [Edwards et al., 2002; Rosen
and Spiegelman, 2001]. Like other nuclear hormone
receptors, PPARs are involved in protein-protein
interactions with coactivators and corepressors, and such
interactions are crucial for mediating physical association
between PPAR-RXR heterodimers with chromatin and
the basic transcription machinery [Rosen and Spiegelman,
2001]. PPAR coactivators include CBP/p300 [Debril et
al., 2004; Flanagan et al., 2005; Ko et al., 2000; Lemon
et al., 2001; Salma et al., 2004; Zhu et al., 1996], steroid
receptor coactivator (SRC)-1 [Gelman et al., 1999; Kung
et al., 2000; Lickert et al., 2004; Lim et al., 2004;Yao et
al., 1998; Zhu et al., 1996], steroid receptor coactivator
(SRC)-2 [Gelman et al., 1999; Lim et al., 2004], steroid
receptor coactivator (SRC)-3 [Lim et al., 2004; Mizukami
and Taniguchi, 1997], PPARγ coactivator (PGC)-1α [Li
et al., 1997; Louet et al., 2006; Puigserver et al., 1998],
PPARγ coactivator (PGC)-1β [Qi et al., 1999], PPAR
binding protein (PBP or TRAP220) [Lim et al., 2004;
Puigserver and Spiegelman, 2003; Surapureddi et al.,
2002; Zhu et al., 1997], PPAR interacting protein (PRIP)
[Goo et al., 2003; Lee et al., 1999], PRIC285 [Kim et al.,
2003; Ko et al., 2000], PRIC320 [Lee et al., 2001],
BAF60c [Debril et al., 2004], and FK614 [Fujimura et al.,
2005]. Nuclear receptor corepressor (NCoR) [Guan et
al., 2005; Horlein et al., 1995;Yu et al., 2005], silencing
mediator of retinoic acid and thyroid hormone receptor
(SMRT) [Chen et al., 1996;Yu et al., 2005], small
heterodimer partner (SHP) [Nishizawa et al., 2002; Shin
and Osborne, 2008;Yamagata et al., 2007],
receptor-interacting protein 140 (RIP140) [Debevec et
al., 2007; Lim et al., 2004], and SIRT-1 [Picard et al.,
2004] are among the well-characterized corepressors
that interact with PPAR-RXR heterodimers, inhibiting
transcriptional transactivation driven by active PPAR-RXR
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(DAX-1), an atypical nuclear receptor, has been recently
shown to function as a transcriptional corepressor of
PPARγ by competing with the PPARγ coactivator (PGC)-1
leading to abrogated adipogenesis in 3T3-L1 cells [Kim
et al., 2008].
Upon binding of PPAR-RXR heterodimers to PPREs of
target genes, coactivators with histone acetylase activity
bind to the ligand- and DNA-bound PPAR-RXR
heterodimer. Such binding is thought to cause chromatin
remodeling, giving access to other coactivators such as
PBP, which connect the PPAR-RXR complex to the basic
transcription machinery, leading to gene transactivation.
In contrast, corepressors bind to ligand- and DNA-bound
PPAR-RXR heterodimers and allow recruitment of histone
deacetylases and/or conformational alterations that
ultimately confer a condensed, inactive chromatin
structure, leading to transcriptional repression [Chen and
Li, 1998; Glass and Rosenfeld, 2000; Hu and Lazar, 2000;
Rosenfeld and Glass, 2001].
Similar to PPARs, LXRs are involved in protein-protein
interactions with coactivators and corepressors, which
upon ligand binding to LXRs, take advantage of
conformational changes that allow their recruitment
[Edwards et al., 2002]. Coactivators and corepressors of
LXRα lead to transcriptional activation and repression of
LXR target genes by means of chromatin remodeling
[Edwards et al., 2002]. Apparently, LXRs interact with
coactivators (PGC-1, SRC-1, and CBP/p300) and
corepressors (NCoR, SMRT, and SHP) that bind PPARs
[Astapova et al., 2008; Brendel et al., 2002; Ghisletti et
al., 2009; Hu et al., 2003; Phelan et al., 2008; Unno et
al., 2005;Wagner et al., 2003]. Recently, RIP-140 has
be demonstrated to be a vital coregulator for LXR activity,
serving as a coactivator or a corepressor of LXR
transcriptional activity in the liver depending on the target
genes and metabolic processes [Herzog et al., 2007].
Some studies have also suggested that corepressors are
constitutively bound to PPARs and LXRs, and upon ligand
binding, conformational changes force simultaneous
dissociation of corepressors and recruitment of
coactivators [Albers et al., 2006; Edwards et al., 2002;
Glass and Rosenfeld, 2000]. Interaction between nuclear
receptors and their coactivators requires multiple LXXLL
motifs located within NR boxes of coactivators [Heery et
al., 1997; Le Douarin et al., 1996; McKenna and O'Malley,
2002;Torchia et al., 1997]. Slight differences within such
NR boxes are critical determinants of nuclear hormone
receptor (NHR)-coactivator specificity [Chen et al., 2000;
Ding et al., 1998; Li et al., 2007; McInerney et al., 1998;
Torchia et al., 1997]. Likewise, corepressors of NHRs
contain small peptide motifs (CoRNR boxes) that mediate
protein-protein interaction with NHRs, and subsequently
transcriptional repression of target genes [Hu and Lazar,
1999]. Despite their remarkable sequence homology,
CoRNR boxes within different corepressors have unique
sequences, an important determinant in NHR-corepressor
specificity [Cohen et al., 2001; Hodgson et al., 2008; Hu
et al., 2001].
With regard to gene expression regulation by estrogen
receptor (ER), differential recruitment of coactivators and
corepressors has been proposed as an explanation for
the target gene and cell type selectivity [Shang and
Brown, 2002]. Likewise, mounting evidence suggest that
the differential recruitment and interaction of coactivators
and corepressors may be a crucial determinant in
modulating the expression of target genes by PPARγ
[Burgermeister et al., 2006; Cock et al., 2004; DiRenzo
et al., 1997; Fujimura et al., 2005; Fujimura et al., 2006;
Miller and Etgen, 2003; Oberfield et al., 1999; Rangwala
and Lazar, 2002;Wigren et al., 2003; Zhang et al., 2007]
and LXR [Albers et al., 2006; Jaye et al., 2005; Miao et
al., 2004; Phelan et al., 2008; Quinet et al., 2004; Schmidt
et al., 2006;Traves et al., 2007;Williams et al., 2003].
SUMOylation-mediated transrepression
of PPARγ and LXRs target genes
SUMOylation is posttranslational modification process by
which a small ubiquitin-like modifier (SUMO) (~20 kDa)
is covalently conjugated to lysine residues on target
proteins [Dohmen, 2004; Hay, 2005; Mabb and Miyamoto,
2007]. SUMOylation involves three enzymatic steps that
proceed sequentially, ultimately leading to SUMO
conjugation to the target protein by forming an isopeptide
bond between SUMO and the ε-amino group of a lysine
side chain [Liu and Shuai, 2008]. Modification of
transcription factors by SUMOylation has been proposed
as a mechanism to modulate the transactivation and/or
transrepression potential of several transcription factors
[Kotaja et al., 2002; Leuenberger et al., 2009; Ling et al.,
2004; Nishida and Yasuda, 2002; Rytinki and Palvimo,
2009]. In 2004, and using different cell models, three
research groups have independently reported that
PPARγ2 is subject to SUMOylation via conjugation with
SUMO-1 at K
107 in the AF-1 domain, and that PPARγ2
SUMOylation significantly inhibits its transcriptional activity
[Floyd and Stephens, 2004; Ohshima et al., 2004;
Yamashita et al., 2004]. A year later, Glass and
colleagues have proposed SUMOylation of PPARγ and
LXRs as a molecular mechanism that underlies the
corepressor-dependent transrepression of PPARγ and
LXRs target genes in macrophages [Ghisletti et al., 2007;
Pascual et al., 2005]. According to the proposed
mechanism, ligand binding triggers SUMOylation of the
LBD of PPARγ and LXRs, subsequently leading to PPARγ
and LXRs recruitment to corepressor complexes (e.g.,
NCoR and HDAC3) on target genes. As a consequence,
signal-dependent removal of corepressor complexes,
which is mediated by ubiquitination and proteasome
degradation, is interfered with in a way that prevents gene
transactivation. Hence, the promoters of target genes
remain occupied by the corepressor complexes, and the
target genes are forced to settle in a repressed state.
In a study performed by Pascual and colleagues, it was
demonstrated that PIAS1, a SUMO E3 ligase, is critical
in PPARγ1-dependent transrepression of iNOS in
macrophages [Pascual et al., 2005]. In that study, it was
also shown that suppressed expression of Ubc9, the
rate-limiting E2 ligase in the SUMOylation pathway, is
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transrepression of iNOS in macrophages [Pascual et al.,
2005]. Interestingly, the potential of rosiglitazone to retain
the repressor NCoR on the iNOS promoter in the
presence of LPS is dependent on PIAS1 and Ubc9
[Pascual et al., 2005]. Using site-directed mutagenesis,
Pascual and colleagues have also shown that K
365, unlike
K
77, is the major SUMOylation site in PPARγ1 and that it
is crucial for mediating transrepression of iNOS [Pascual
et al., 2005].These findings clearly indicate that
PIAS1/Ubc9-mediated SUMOylation is an essential
process involved in transrepression of PPARγ1 target
genes in macrophages.
Intriguingly, this proposed mechanism of transrepression
is not unique to PPARγ, since LXR transrepression of
inflammatory target genes also utilizes a
SUMOylation-dependent pathway [Ghisletti et al., 2007].
Yet, the key players involved in SUMOylation-dependent
transrepression by PPARγ and LXRs are not identical.
Specifically, while PPARγ is SUMOylated by SUMO-1,
LXR is SUMOylated by SUMO-2 and SUMO-3 [Ghisletti
et al., 2007]. Additionally, while PIAS1 serves as the main
SUMO E3 ligase in SUMOylation-dependent
transrepression by PPARγ, SUMOylation-dependent
transrepression by LXR requires HDAC4 as the main
SUMO E3 ligase [Ghisletti et al., 2007]. Like PPARγ,
knockdown of Ubc9 leads to a significant impairment of
LXR ligand-dependent transrepression of iNOS in
LPS-treated macrophages due to impaired LXR
recruitment to the iNOS promoter leading to retained
NCoR binding [Ghisletti et al., 2007]. Site-directed





448 in LXRβ are the key SUMOylation
target sites, and that lysine to arginine substitutions of
these residues is accompanied by significant impairment
of LXR ligand-dependent transrepression of iNOS in
macrophages [Ghisletti et al., 2007]. Ghisletti and
colleagues also concluded that the parallel
SUMOylation-dependent transrepression pathways
mediated by PPARγ and LXRs are themselves subject
to regulation, and can be overridden by specific signals
in a gene-specific manner. It is worth mentioning that
interference with SUMOylation has no effect on the
transactivation potential of PPARγ and LXRs towards
their target genes in macrophages [Ghisletti et al., 2007;
Pascual et al., 2005].These findings provide a plausible
explanation of the similar, but functionally distinctive
potential of PPARγ and LXRs to regulate a specific set
of target genes involved in key physiological processes
such as inflammation and metabolic homeostasis. In a
recent study, Jennewein and colleagues have
demonstrated that SUMOylation of PPARγ in apoptotic
cells prevents LPS-induced NCoR removal from κB
binding sites within the promoters of pro-inflammatory
genes, mediating transrepression of pro-inflammatory
cytokines [Jennewein et al., 2008].Taken together, there
is mounting experimental evidence indicating that
SUMOylation of PPARγ and LXRs on key lysine residues
mediates transrepression of PPARγ and LXRs target
genes in many cell types, and that this regulation can be
differentially controlled to fine-tune the cellular outcomes
in response to ligand binding.
Role of PPARγ1 and LXRα in
macrophage cholesterol homeostasis
PPARγ1 and LXRα are known to be potent sterol and
fatty acid sensors that play fundamental roles in lipid
metabolism. PPARγ/LXRα signaling pathways are
involved in various key biological processes that are
implicated in many conditions such as obesity, diabetes
mellitus, atherosclerosis, and inflammatory diseases [Cao
et al., 2004;Walczak and Tontonoz, 2002]. Both PPARγ1
and LXRα are expressed abundantly in macrophages,
especially in lipid-laden foam cells within atherosclerotic
lesions [Ricote et al., 1998a;Tontonoz et al., 1998;
Venkateswaran et al., 2000b].
Upon uptake of oxLDL by macrophages, many
intermediates such as oxidized fatty acids and oxysterols
are formed, providing macrophages with PPARγ1 and
LXRα natural ligands [Fu et al., 2001b; Janowski et al.,
1999; Nagy et al., 1998].Thus, PPARγ1 and LXRα
become ligand-bound and heterodimerize with their
obligate RXR molecules to become transcriptionally
active. In fact, oxLDL does not only lead to PPARγ1 and
LXRα activation, but it also leads to increased expression
of these genes [Ricote et al., 1998a;Tontonoz et al.,
1998]. In turn, PPARγ1 and LXRα signaling pathways
are turned on, leading to the transactivation of a cascade
of genes whose products are critically involved in
cholesterol efflux in macrophages (Figure 1).
ABCs are direct downstream targets of
PPARγ1 and LXRα in macrophages
Members of the ATP-binding cassette (ABC) family of
proteins are among the most extensively studied
downstream targets of the PPARγ1-LXRα signaling
pathway initiated by lipid loading in macrophages. ABCs
are transmembrane proteins with two ATP-binding
domains and 12 membrane-spanning domains, and they
function as efficient cholesterol transporters by forming
channel-like structures in the plasma membrane
[Decottignies and Goffeau, 1997]. ABCs are involved in
active transport of cholesterol from inside the cell onto
HDL particles. In macrophages, ABCA1 and ABCG1 play
major roles in HDL-mediated and ApoAI-mediated
cholesterol efflux [Brooks-Wilson et al., 1999; Lawn et
al., 1999]. Lipid loading of macrophages increases the
expression of ABCA1 [Langmann et al., 1999] and
ABCG1 [Klucken et al., 2000;Venkateswaran et al.,
2000b].The importance of ABCA1 function as a
cholesterol efflux mediator is illustrated by Tangier
disease, a genetic disorder characterized by extremely
low plasma HDL levels and remarkable accumulation of
cholesterol in macrophages localized in the tonsils,
spleen, liver, and intestine [Serfaty-Lacrosniere et al.,
1994]. Numerous studies have demonstrated that familial
Tangier disease mainly results from mutations in the
ABCA1 gene [Altilia et al., 2003; Bodzioch et al., 1999;
Brooks-Wilson et al., 1999; Guan et al., 2004; Hooper et
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are synthesized, which allows activation of PPARγ1 and LXRα. Once activated, PPARγ1 and LXRα not only induce the expression of each other, but
they also induce the expression of many ABC transporters, as well as that of ApoE. ABCs and ApoE play integral roles in transferring excess cholesterol
to its acceptor, HDL, and this initiates the process of reverse cholesterol transport (RCT). In RCT, excess peripheral cholesterol is scavenged by tissue
macrophages, which process cholesterol and transport it to the liver via HDL for excretion.
al., 2009; Maekawa et al., 2009; Rust et al., 1998;
Singaraja et al., 2006]. Moreover, macrophages isolated
from Tangier patients express significantly lower levels
of ABCG1 [Lorkowski et al., 2001]. Interestingly,
pharmacological activation of PPARγ1 and/or LXRα in
macrophages cannot overcome ABCA1 deficiency, which
completely abolishes cholesterol efflux [Chinetti et al.,
2001]. Experimental evidence exists indicating that
reduced levels of ABCG1 correlate with inhibited
cholesterol efflux in macrophages [Mauldin et al., 2008;
Wang et al., 2004]. Clearly, ABCs are involved in the first
step of reverse cholesterol transport (RCT), and they are
also involved in the control of total plasma HDL levels,
major events associated with atherogenesis. Interestingly,
about 40% of Tangier patients develop symptoms of
atherosclerosis at one point in their life
[Serfaty-Lacrosniere et al., 1994].
Studies have shown that PPARγ1 and LXRα are involved
in a positive, reciprocal relationship, in which the
activation of one of them leads to the upregulation of the
other [Chawla et al., 2001b; Seo et al., 2004]. However,
experimental evidence suggests that ABCA1 and ABCG1
are not direct targets of PPARγ1 in macrophages, and
that PPARγ1 activation leads to induction of ABCA1 and
ABCG1 levels via LXRα upregulation [Chawla et al.,
2001b]. Actually, Chawla and colleagues have shown
that LXRα activation results in marked induction of ABCA1
and ABCG1 in PPARγ1-deficient macrophages, indicating
that PPARγ1 is dispensable for LXRα-mediated
upregulation of ABC proteins in macrophages [Chawla
et al., 2001b]. In concert, PPARγ1 deficiency had no effect
on the ability of 22(R)-hydroxycholesterol, an LXR agonist,
to induce ABCA1 and ABCG1 expression in macrophages
[Akiyama et al., 2002]. In addition, LXRα-deficient
macrophages display diminished cholesterol efflux due
to lack of upregulation of ABCA1 [Repa et al., 2000b],
and ABCG1 [Laffitte et al., 2001], confirming that PPARγ1
is insufficient in upregulating ABCA1 and ABCG1 in the
absence of LXRα. However, studies using PPARγ1
conditional knockout mice revealed that PPARγ1-deficient
macrophages have reduced LXRα, ABCA1, and ABCG1
levels, and thus, diminished cholesterol efflux, and they
develop into foam cells [Akiyama et al., 2002; Chawla et
al., 2001b].These studies suggest a complex, regulatory
loop implicating PPARγ1 and LXRα as key, upstream
players in a signaling pathway that culminates in
upregulation of ABC proteins and cholesterol clearance
from macrophages.
It is important to note that both forms of LXR, LXRα and
LXRβ, have been shown to play comparable roles in
macrophages with regard to ABCA1 induction and
cholesterol efflux [Costet et al., 2000; Joseph et al., 2004;
Mak et al., 2002; Peet et al., 1998b; Repa et al., 2000a;
Schwartz et al., 2000;Venkateswaran et al., 2000a;
Walczak et al., 2004]. Consistently, in vivo studies have
shown that LXRα and LXRβ exert comparable
atheroprotective effects, in which both forms must be
deleted to induce atherogenesis in mice [Schuster et al.,
2002]. Along the same line, another study has
demonstrated that ablation of both LXRα and LXRβ is
essential to promote atherosclerosis in ApoE
-/- and LDLR
-/-
mice [Tangirala et al., 2002]. Although a few studies have
recently suggested partial differential effects of LXRα and
LXRβ with regard to regulation of macrophage cholesterol
efflux regulators [Lund et al., 2006], non-redundant roles
of these two forms of LXR are still unclear.The
development and use of LXRα-selective and
LXRβ-selective agonists [Lund et al., 2006; Miao et al.,
2004; Quinet et al., 2006; Szewczyk et al., 2006] is
ongoing in an attempt to provide a lucid answer to the
question whether LXRα and LXRβ play redundant roles
in macrophage cholesterol homeostasis and
atherogenesis.
ApoE is a direct downstream target of
PPARγ1 and LXRα
An extensive body of literature demonstrates that ApoE,
which is expressed abundantly in macrophages, is a
prominent player in macrophage cholesterol efflux and
foam cell formation [Basu et al., 1983; Basu et al., 1982;
Dory, 1989; Lin et al., 1999; Mazzone and Reardon, 1994;
Zhang et al., 1996b]. ApoE-deficient macrophages display
severely diminished ability to efflux cholesterol and other
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et al., 2000; Mazzone, 1996;Van Eck et al., 2000],
indicative of a key role of ApoE in RCT. Noteworthy, the
PPARγ1-LXRα-ABC signaling pathway described above
also leads to upregulation of ApoE in macrophages, as
suggested by many independent studies. It was shown
that basal expression of ApoE is attenuated in
PPARγ1-deficient macrophages, indicating that PPARγ1
positively regulates ApoE expression [Akiyama et al.,
2002]. In addition, treatment of THP-1 macrophages with
ciglitazone, a potent PPARγ agonist, results in a
significant increase in ApoE levels [Galetto et al., 2001],
indicating that PPARγ1 activity positively correlates with
ApoE expression in macrophages. However, treatment
of PPARγ1-deficient macrophages with
22(R)-hydroxycholesterol, a natural LXRα agonist,
induces ApoE expression, and thus, bypasses PPARγ1
dependency [Akiyama et al., 2002]. Another line of
evidence indicates that 22(R)-hydroxycholesterol and
synthetic LXR agonist T0901317 upregulate ApoE
expression in wildtype, but not LXRα-deficient,
macrophages, confirming that ApoE upregulation in
macrophages is LXRα-dependent, consistent with the
fact that the ApoE promoter contains consensus LXRE
[Laffitte et al., 2001]. Despite the presence of PPRE within
the promoter region of ApoE [Galetto et al., 2001], solid
evidence indicating a direct PPARγ1-mediated
upregulatory effect on ApoE expression is lacking.
Collectively, these studies suggest that activation of
PPARγ1 leads to induction of ApoE expression via LXRα
upregulation, and that ApoE is a major component of the
PPARγ1-LXRα signaling paradigm. Noteworthy, defects
in any component of the PPARγ1-LXRα signaling pathway
in macrophages render cholesterol efflux defective, and
thus, result in the transformation of macrophages into
lipid-laden foam cells.
AEBP1 impedes macrophage
cholesterol homeostasis by suppressing
PPARγ1 and LXRα
AEBP1 gene is located on chromosome 7 and 11 in the
human and mouse genomes, respectively.Through
alternative splicing, AEBP1 gene is transcribed to yield
two related, but distinct, transcripts. One transcript is
translated into an 82-kDa protein, AEBP1, while the other
transcript is translated into a 175-kDa protein, ACLP
(aortic carboxypeptidase-like protein), which has an
additional 380-amino acid coding sequence at its
N-terminus [Ro et al., 2001]. ACLP was initially identified
in human aortic smooth muscle cells, and its protein
expression can only be detected in the aorta [Layne et
al., 1998] and adipose tissue [Layne et al., 2001]. Cell
fractionation and immunofluorescent staining experiments
revealed that ACLP is excluded from the nucleus and
localized in the perinuclear space, indicative of its entry
into the secretory pathway [Layne et al., 2001]. Unlike
ACLP, which is targeted to the extracellular matrix (ECM)
[Layne et al., 2001], due to the presence a lysine- and
proline-rich 11-amino acid repeating motif and a signal
sequence [Layne et al., 1998], AEBP1 is an intracellular
protein that exists in the cytoplasm and the nucleus
[Majdalawieh et al., 2007; Park et al., 1999]. AEBP1
protein is composed of three main domains: a
discoidin-like domain (DLD) at its N-terminus, a central
carboxypeptidase (CP) domain, and a structurally
uncharacterized C-terminal DNA-binding domain [He et
al., 1995].The C-terminal domain of AEBP1 is divided
into three distinct subdomains: a lysine- and arginine-rich
basic region, a serine-, threonine-, and proline-rich region,
and a glutamate-rich acidic region towards the end. Unlike
ACLP, AEBP1 is ubiquitously expressed in many tissues
and cells, and its expression seems to be highest in white
and brown adipose tissues, liver, lung, spleen, brain, and
macrophages [Majdalawieh and Ro, 2009; Majdalawieh
et al., 2006; Majdalawieh et al., 2007; Ro et al., 2001].
According to the model proposed by Chawla and
colleagues, uptake of oxLDL leads to PPARγ1 and LXRα
activation in macrophages [Chawla et al., 2001b]. LXRα
directly upregulates ABCA1, ABCG1, and ApoE
expression, promoting cholesterol clearance from
macrophages. Studies from our laboratory have
demonstrated that AEBP1 modulates macrophage
cholesterol homeostasis by its ability to downregulate
PPARγ1 and LXRα expression and transcriptional activity
[Majdalawieh and Ro, 2009; Majdalawieh et al., 2006].
Both endogenous and exogenous overexpression of
AEBP1 have been accompanied by significant reduction
in PPARγ1 and LXRα levels [Majdalawieh and Ro, 2009;
Majdalawieh et al., 2006]. Indeed, mutagenesis analysis
revealed that PPARγ1 and LXRα repression by AEBP1
is DNA-binding-dependent, in which the C-terminus of
AEBP1 is crucial for such AEBP1 suppressive effects
[Majdalawieh et al., 2006]. Consistent with its ability to
repress PPARγ1 and LXRα, AEBP1 overexpression and
ablation lead to decreased and increased levels of
ABCA1, ABCG1, and ApoE in macrophages, respectively
[Majdalawieh and Ro, 2009; Majdalawieh et al., 2006].
As expected, inhibited expression of ABCA1, ABCG1,
and ApoE via PPARγ1, and LXRα transcriptional
repression by AEBP1, results in inefficient cholesterol
efflux from macrophages [Majdalawieh et al., 2006].
Indeed, macrophages that overexpress AEBP1 (AEBP1
TG
macrophages) accumulate considerable amounts of lipids
in their cytoplasmic compartments compared to their
control counterparts (AEBP1
NT macrophages)
[Majdalawieh et al., 2006], indicating that sustained lipid
accumulation is a direct indication of disrupted cholesterol
efflux in macrophages that express significantly
decreased levels of ABCA1, ABCG1, and ApoE due to
AEBP1 overexpression.These findings strengthen the
model proposing that activation of PPARγ1 and LXRα is
essential for upregulated surface expression of ABC
transporters and ApoE, as well as successive removal of
accumulated lipids in macrophages [Chawla et al., 2001b;
Laffitte et al., 2001].Thereby, negative regulation of ApoE
by AEBP1 is consistent with AEBP1-mediated
transcriptional repression of PPARγ1 and LXRα in
macrophages.
PPARγ1 induction of lipid uptake via CD36 and lipid efflux
via LXRα-ABCs raises the question of whether the net
effect of PPARγ1 activation would be to promote or
www.nursa.org  NRS  | 2010 |  Vol. 8 |  DOI: 10.1621/nrs.08004 | Page 6 of 17
Review AEBP1 regulates PPARγ1-LXRα signaling in macrophagesimpede foam cell formation. Although PPARγ1 induces
CD36 upregulation, forcing macrophages to uptake and
accumulate lipids, it concurrently induces expression of
LXRα, ABCs, ApoE, and lipoprotein lipase (LPL), crucial
factors favoring macrophage cholesterol efflux [Akiyama
et al., 2002]. Meaningfully, a bone marrow transplantation
experiment revealed that the PPARγ1-LXRα-ABC efflux
pathway dominates in vivo [Chawla et al., 2001b].
Consistently, AEBP1’s regulatory function in macrophages
supports a protective role of PPARγ1 against foam cell
formation since PPARγ1 downregulation in AEBP1
TG
macrophages is accompanied by decreased levels of not
only LXRα, ABCA1, ABCG1, and ApoE, but also CD36.
Many studies have shown that lipopolysaccharide (LPS)
treatment in macrophages is accompanied by significant
reduction in PPARγ1 levels [Miksa et al., 2007;Welch et
al., 2003; Zhou et al., 2008]. Consistently, LPS was shown
to induce foam cell formation due to disrupted cholesterol
clearance from macrophages [Funk et al., 1993;
Kalayoglu and Byrne, 1998a; Kalayoglu and Byrne,
1998b; Oiknine and Aviram, 1992]. Recently, AEBP1 was
shown to be critical in mediating LPS-suppressive effects
on PPARγ1 and LXRα expression in macrophages
[Majdalawieh and Ro, 2009]. In agreement, AEBP1
ablation is accompanied by attenuated LPS-mediated
suppression of PPARγ1 and LXRα expression in
AEBP1-deficient macrophages [Majdalawieh and Ro,
2009].This regulatory role of AEBP1 seems to be
physiologically significant given that induction of foam
cell formation by LPS is dependent on AEBP1, in which
AEBP1-deficient macrophages are rendered protective
against LPS-induced foam cell formation [Majdalawieh
and Ro, 2009]. Interestingly, LPS treatment was shown
to induce AEBP1 expression in macrophages
[Majdalawieh and Ro, 2009], which may serve as a
mechanism that explains the regulatory role that AEBP1
plays in mediating LPS-suppressive effects on PPARγ1
and LXRα in macrophages.
Anti-inflammatory roles of PPARγ1 and
LXRα
Aside from its imperative role in controlling macrophage
cholesterol homeostasis, PPARγ1 possesses potent
anti-inflammatory functions in macrophages [Lee and
Evans, 2002; Rizzo and Fiorucci, 2006; Zelcer and
Tontonoz, 2006]. A variety of PPARγ synthetic agonists
have been used to demonstrate that PPARγ1 exerts
anti-inflammatory effects in macrophages due to their
ability to suppress the expression of a wide range of
pro-inflammatory genes.Treatment of murine peritoneal
macrophages with 15-deoxy-Δ
12,14-prostaglandin or BRL
49653, specific PPARγ agonists, results in marked
reduction in IFNγ-induced and PMA-induced expression
of iNOS and MMP-9 (also known as gelatinase B),
respectively [Ricote et al., 1998b]. Moreover,
PMA-induced expression of IL-1β, IL-6, and TNFα is
significantly reduced in primary human monocytes treated
with two PPARγ agonists, 15-deoxy-Δ
12,14-prostaglandin
and troglitazone [Jiang et al., 1998].
15-deoxy-Δ
12,14-prostaglandin and troglitazone also lead
to inhibited TNFα promoter-driven expression in the
human monocyte/macrophage cell line U937 [Jiang et
al., 1998]. Numerous studies have shown that activation
of PPARγ1 in macrophages also leads to blocked
expression of IL-12 [Alleva et al., 2002; Chung et al.,
2000], iNOS [Bernardo et al., 2000; Fahmi et al., 2001;
Petrova et al., 1999] and COX-2 [Tsubouchi et al., 2001].
PPARγ1 activation has also been shown to suppress
TGFβ expression [Fu et al., 2001a; Guo et al., 2004; Lee
et al., 2005; Lee et al., 2006; Maeda et al., 2005; Zhao
et al., 2006]. However, the effort of these studies to
present PPARγ1 as a potent anti-inflammatory mediator
is hampered by experiments performed in
PPARγ1-deficient macrophages. Chawla and colleagues
have demonstrated that LPS treatment leads to equivalent
induction of IL-6 and TNFα in wildtype and
PPARγ1-deficient macrophages [Chawla et al., 2001a].
Most importantly, PPARγ1 expression in macrophages
or lack of it had no effect on the ability of
15-deoxy-Δ
12,14-prostaglandin to inhibit LPS-induced
expression of IL-6 and TNFα [Chawla et al., 2001a].
Alternatively, Hinz and colleagues demonstrated that
15-deoxy-Δ
12,14-prostaglandin and ciglitazone resulted in
reduced LPS-induced expression of IL-6, TNFα, and
COX-2 in human monocytes in presence of the PPARγ
antagonist, bisphenol A diglycidyl ether (BADGE) [Hinz
et al., 2003]. Other studies have also demonstrated that
PPARγ1-independent anti-inflammatory effects exerted
by PPARγ agonists in vitro and in vivo [Brunmair et al.,
2001; Chawla et al., 2001a; Lennon et al., 2002; Niino et
al., 2001; Reilly et al., 2000].These findings raised
questions about the exact role of PPARγ1 in macrophage
inflammatory responsiveness. Later studies have shown
that PPARγ agonists exert anti-inflammatory functions in
macrophages via PPARγ1-dependent and
PPARγ1-independent mechanisms depending on the
concentration of agonists and the nature of the
inflammatory signal.When PPARγ agonists are used at
low receptor-specific concentrations, their
anti-inflammatory function seems to be dependent on
PPARγ1 expression [Welch et al., 2003]. At high agonist
concentrations, however, PPARγ1-independent
mechanism(s), possibly involving PPARβ/δ, manifests
anti-inflammatory effects of such PPARγ agonists in
macrophages [Welch et al., 2003].
A strong line of evidence indicates the existence of a vital
crosstalk between macrophage cholesterol homeostasis
and inflammation based on recent studies demonstrating
a direct role of LXRα in mediating anti-inflammatory
effects in macrophages. Using murine peritoneal
macrophages, the LXR agonists T0901317 and GW3965
have been shown to be very effective in inhibiting
LPS-induced expression of a wide range of
pro-inflammatory mediators including IL-1β, IL-6, iNOS,
COX-2, MCP-1, MCP-3, MIP-1β, IP-10, and MMP-9
[Joseph et al., 2003]. Although lack of expression of either
LXRα or LXRβ in macrophages did not interfere with LXR
agonist-mediated inhibition of LPS-induced expression
of these pro-inflammatory mediators, macrophages that
lack both isoforms (i.e., LXRα
-/-LXRβ
-/- macrophages)
were unresponsive to the anti-inflammatory effects
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indicate that the loss of one LXR isoform can be
compensated by the other isoform, and that LXR agonists
exert their anti-inflammatory effects in macrophages in
an LXR-dependent mechanism. Interestingly, in vivo
experiments revealed that LXR-mediated
anti-inflammatory functions are not restricted to
macrophages, since LPS-induced hepatic expression of
IL-6, TNFα, and iNOS, as well as LPS-induced aortic
expression of IL-6, iNOS, and MMP-9 is significantly
elevated in LXRα
-/-LXRβ
-/- mice compared to wildtype
mice [Joseph et al., 2003].
Consistently, LPS-, IL-1β-, and TNFα-induced expression
of MMP-9 is markedly inhibited by T0901317 and
GW3965 in murine peritoneal macrophages [Castrillo et
al., 2003]. Furthermore, T0901317 and GW3965
treatment results in reduced LPS-induced expression
levels of tissue factor (TF) and osteopontin (OPN),
pro-inflammatory, pro-atherogenic mediators, in murine
peritoneal macrophages and RAW 264.7 macrophages,
respectively [Ogawa et al., 2005;Terasaka et al., 2005].
In vivo, LXR agonists are also capable of reducing
LPS-induced TF expression levels in the aorta, kidney,
and lung [Terasaka et al., 2005]. Activation of LXR has
also been shown to reduce inflammation in the aortae of
atherosclerotic mice [Joseph et al., 2002] and in a mouse
model of contact dermatitis [Fowler et al., 2003]. Recently,
the LXR agonists have been shown to suppress lung
inflammatory responses via inhibiting the expression of
inflammatory genes in alveolar macrophages [Birrell et
al., 2007; Smoak et al., 2008].
NF-κB role in PPARγ1- and
LXRα-mediated anti-inflammation
Despite the strong evidence behind the anti-inflammatory
effects of selective PPARγ and LXR agonists, the exact
mechanism underlying such effects is poorly understood.
Strong evidence suggests that activation of PPARγ1
and/or LXRα interferes with NF-κB, STAT, and AP-1
activity in macrophages [Bonfield et al., 2008; Castrillo
et al., 2003; Chang et al., 2007; Chinetti et al., 1998;
Joseph et al., 2003; Park et al., 2009; Ricote et al., 1998b;
Straus et al., 2000;Welch et al., 2003; Zhou and
Waxman, 1999]. Mechanisms leading to inhibited NF-κB
activity by PPARγ agonists in macrophages include
inhibited IKK activity, and thus, decreased IκBα
phosphorylation [Straus et al., 2000;Wang et al., 2007;
Zingarelli et al., 2003], covalent modifications of NF-κB
subunits leading to abrogated NF-κB-DNA interaction
[Chung et al., 2000], and induced NF-κB nuclear export
[Kelly et al., 2004]. Indeed, it was shown that PPARγ1 is
capable of interfering with NF-κB activity by interacting
with NF-κB subunits, rendering NF-κB transcriptionally
inactive [Chung et al., 2000]. Furthermore, PPARγ
agonists may be capable of modulating NF-κB activity by
means of alkylation of cysteine residues located in the
DNA-binding domains of NF-κB subunits (C
62 in p50 and
C
38 in p65) [Straus et al., 2000]. It was also suggested
that PPARγ agonists lead to enhanced MAPK activation,
and subsequently more phosphorylation of PPARγ1,
which is more efficient in interacting with NF-κB when
phosphorylated [Chen et al., 2003]. However, other
studies have demonstrated that PPARγ agonists impede
NF-κB signaling via PPARγ1-independent mechanisms.
In a study performed in RAW 264.7 macrophages, which
lack endogenous PPARγ1, 15-deoxy-Δ
12,14-prostaglandin
treatment resulted in significant inhibition of NF-κB activity
[Straus et al., 2000], suggesting that PPARγ1 is not
required for PPARγ agonist-mediated anti-inflammatory
effects in macrophages. Hence, it is not surprising that
the importance of PPARγ1 involvement in NF-κB inhibition
by PPARγ agonists is very controversial. Interestingly,
many studies have also shown that activation of
IKK/NF-κB pathway results in abrogated PPARγ1
transcriptional activity [Gao et al., 2006; Ruan et al., 2003;
Suzawa et al., 2003;Torti et al., 1989; Zhang et al.,
1996a].
The pro-inflammatory role of AEBP1 is
independent of its ability to suppress
PPARγ1 and LXRα in macrophages
The ability of AEBP1 to induce macrophage inflammatory
responsiveness leading to enhanced expression of
pro-inflammatory mediators (e.g., IL-6, TNFα, MCP-1,
and iNOS) [Majdalawieh et al., 2006] has been attributed
to its potential to promote NF-κB activity [Majdalawieh et
al., 2007]. Since interference with NF-κB activity has been
proposed as a mechanism underlying the
anti-inflammatory effects of PPARγ1 and LXRα [Castrillo
et al., 2003; Chang et al., 2007; Chinetti et al., 1998;
Joseph et al., 2003; Park et al., 2009; Ricote et al., 1998b;
Straus et al., 2000;Welch et al., 2003; Zhou and
Waxman, 1999], it is plausible for one to speculate that
AEBP1-mediated suppression of PPARγ1 and LXRα may
be a direct cause of ABEP1’s ability to upregulate NF-κB
activity in macrophages. However, this possibility is ruled
out in light of mutagenesis analyses showing that the
C-terminus mutant form of AEBP1, which is incapable of
suppressing PPARγ1 and LXRα [Majdalawieh et al.,
2006], is as effective as full-length AEBP1 in promoting
NF-κB activity [Majdalawieh et al., 2007]. In agreement,
the N-terminus mutant form of AEBP1 is capable of
suppressing PPARγ1 and LXRα [Majdalawieh et al.,
2006], yet it has no upregulatory effect on NF-κB activity
[Majdalawieh et al., 2007]. Collectively, AEBP1’s ability
to promote macrophage inflammatory responsiveness
via NF-κB upregulation is not attributed to
AEBP1-mediated suppression of PPARγ1 and LXRα in
macrophages.
Concluding remarks
Experimental evidence suggests that AEBP1 manifests
itself as a critical regulator of macrophage cholesterol
homeostasis and macrophage inflammatory
responsiveness, and thus, as a potent pro-atherogenic
factor.The pro-atherogenic properties exhibited by
AEBP1 seem to be a byproduct of a vital interplay of its
ability to antagonize PPARγ1 and LXRα cholesterol efflux
functions in macrophages and its ability to promote
macrophage inflammatory responsiveness via
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AEBP1-mediated attenuation of IκBα inhibitory function.
Bone marrow transplantation experiments using ApoE
-/-
mice and analysis of atherosclerotic lesion formation in
AEBP1
-/-/LDLR
-/- hybrid mice are currently underway to
elucidate the pro-atherogenic potential of AEBP1 in vivo.
Interestingly, AEBP1 expression was previously shown
to be negligible in monocytes and that its expression is
significantly upregulated during monocyte differentiation
into macrophages [Majdalawieh and Ro, 2009].
Interestingly, monocytes differentiation is also
accompanied by upregulation of PPARγ1 and LXRα
expression [Kohro et al., 2000; Langmann et al., 2005;
Marx et al., 1998; Quinet et al., 2004; von Knethen et al.,
2007;Whitney et al., 2001; Zhu et al., 1998]. Given that
AEBP1 level is hardly detectable in monocytes and
considering the parallel upregulation of AEBP1, as well
as PPARγ1 and LXRα expression, during monocyte
differentiation, we believe that AEBP1 plays vital
regulatory roles in macrophages, but not in monocytes.
AEBP1 is proposed to serve as an indispensable regulator
in the PPARγ1-LXRα signaling pathway that is critically
involved in cholesterol clearance from macrophages; the
initial step in reverse cholesterol transport. Under normal
physiological conditions, AEBP1 fine-tunes the expression
and transcriptional activity of PPARγ1 and LXRα in
macrophages so that cholesterol homeostasis is
maintained. Similarly, and given the vital roles of PPARγ1
and LXRs in macrophage inflammation, AEBP1 may have
evolved to serve as a check point for regulating the
expression of various pro-inflammatory and
anti-inflammatory mediators in macrophages. Noteworthy,
cholesterol and oxysterol accumulation in macrophages
has been shown to trigger apoptosis of lipid-laden
macrophages [Colles et al., 1996; Fazio et al., 2001;
Lordan et al., 2009; Panini and Sinensky, 2001;Tabas,
2002]. It is intriguing to propose that foam cell formation
may be induced via upregulating AEBP1 expression, and
thus impeding cholesterol efflux through PPARγ1 and
LXRα downregulation, in cases where macrophage
apoptosis is physiologically desired.
Recently, AEBP1 expression was shown to be induced
by LPS, and that LPS-induced downregulation of PPARγ1
and LXRα, leading to foam cell formation, is largely
mediated by AEBP1 [Majdalawieh and Ro, 2009].This
suggests that Gram positive bacteria-induced
atherosclerosis may be mediated by LPS ability to
manipulate AEBP1 expression in macrophages, leading
to attenuated PPARγ1-LXRα signaling and subsequently
foam cell formation and atherosclerosis.The regulatory
role that AEBP1 plays in controlling macrophage
cholesterol homeostasis and metabolism is consistent
with the documented effects of AEBP1 in adiposity and
energy metabolism [Ro et al., 2007; Zhang et al., 2005].
Because the entire AEBP1 amino acid sequence is
encoded in ACLP, both proteins seem to play similar roles
in key biological processes, in which both proteins
promote proliferation of preadipocytes and inhibit their
differentiation into mature, fat-filled adipocytes [Gagnon
et al., 2002; He et al., 1995]. Nonetheless, AEBP1 and
ACLP play very distinctive and unique roles in other
biological processes [Layne et al., 1998; Layne et al.,
2001; Majdalawieh and Ro, 2009; Majdalawieh et al.,
2006; Majdalawieh et al., 2007; Ro et al., 2007; Schissel
et al., 2009; Zhang et al., 2005]. Notably, none of the
regulatory roles that AEBP1 plays in macrophages can
be exercised by ACLP since it is an extracellular
matrix-associated secretory protein that is excluded from
the nuclear and cytoplasmic compartments of mouse
aortic smooth muscle cells [Layne et al., 2001] and it is
not expressed in primary macrophages or J774
macrophage cell line [Majdalawieh et al., 2007].Thus,
although ACLP shares the exact C-terminal DNA-binding
domain of AEBP1, it is not possible for ACLP to function
as a transcriptional repressor due to its absence in the
nucleus, and hence, it is inconceivable that ACLP can
repress the expression of PPARγ1 and LXRα in
macrophages. Likewise, since ACLP is not a cytosolic
protein, it is inconceivable that ACLP can have any effect
on IκBα function or NF-κB activity, despite the fact that
both AEBP1 and ACLP share DLD; the domain that
mediates AEBP1-IκBα interaction in macrophages
[Majdalawieh et al., 2007]. Moreover, it is important to
emphasize that the repressed expression of PPARγ1 and
LXRα, the disrupted cholesterol efflux, and the enhanced
inflammatory responsiveness associated with AEBP1
TG
macrophages [Majdalawieh et al., 2006] can only be
attributed to AEBP1, not ACLP, since AEBP1 targeted
overexpression is driven by a transgene carrying AEBP1
cDNA [Zhang et al., 2005].Thus, despite the fact that
they are transcribed from the same gene and share
identical structural domains, AEBP1 and ACLP display
differential expression pattern, cellular localization, and
physiological function.
Clearly, further in vitro and in vivo studies are needed to
shed more light on the exact molecular and physiological
mechanisms by which AEBP1 manifests its regulatory
effects on pivotal factors involved in macrophage biology
and metabolism. Finally, we anticipate that AEBP1 may
be considered as a potential molecular target to
manipulate macrophage behavior and develop therapeutic
strategies for the prevention or treatment of metabolic
and inflammatory conditions.
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